Bausch Health Companies Inc Dossier
Qualitative Analysis
Business overview
Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals International, Inc.) is a global diversified specialty pharmaceutical and medical device company headquartered in Laval, Canada. The company researches, develops, manufactures, and markets a broad portfolio of products primarily in the therapeutic areas of gastroenterology, hepatology, neurology, dermatology, and eye health. Its operations are organized into five reportable segments: Salix (focusing on GI products in the U.S., led by its flagship product Xifaxan), International (covering sales outside the U.S. excluding Bausch + Lomb and Solta Medical), Solta Medical (aesthetic medical devices), Diversified Products (U.S. neurology, dermatology, generics, and dentistry), and Bausch + Lomb (global eye health business). Bausch Health holds an approximate 88% majority ownership stake in Bausch + Lomb Corporation, which operates as an independent publicly traded entity.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the clinical development of larsucosterol (acquired via DURECT Corporation), a novel epigenetic modulator with FDA Breakthrough Therapy Designation, for the treatment of severe alcohol-associated hepatitis (AH).
Expected impact: Establishes a late-stage hepatology pipeline asset addressing a high unmet medical need with no currently approved therapies.
Integrating Wuhan Shibo Zhenmei Technology Co., Ltd. (the Shibo group) as a wholly owned subsidiary to assume direct responsibility for the distribution of Solta Medical's aesthetics portfolio (including Thermage FLX) in China.
Expected impact: Expands geographical reach, provides direct access to a large customer base, accelerates localized solutions, and captures higher margin direct sales in the fast-growing Chinese aesthetics market.
Securing public drug plan coverage across Canada for PrOKEDI (Risperidone extended-release injectable suspension) 75mg and 100mg for the treatment of schizophrenia in adults.
Expected impact: Enables broad public reimbursement-backed patient access across Canada, driving market adoption and neuropsychiatry segment growth.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To acquire DURECT's lead asset, larsucosterol, a novel epigenetic modulator with FDA Breakthrough Therapy Designation for severe alcohol-associated hepatitis, strengthening Bausch Health's late-stage hepatology pipeline.
Financial impact: Upfront cash consideration of approximately $63 million, with potential net sales milestone payments of up to $350 million in the aggregate.
To transition Solta Medical's aesthetics distribution in China from a third-party model to direct-to-market, capturing direct customer insights and expanding market scale for Thermage FLX.
Financial impact: Total estimated aggregate acquisition consideration of approximately $87 million. Contributed to Solta segment's 51% reported revenue growth in Q1 2026.
Strategic Partnerships
Successfully completed negotiations resulting in a Letter of Intent (LOI) for public drug plan coverage of PrOKEDI 75mg and 100mg in Canada, moving the drug closer to public coverage and commercial launch.
Terms: Terms of the LOI establish the framework for finalizing Product Listing Agreements with individual Canadian federal, provincial, and territorial drug plans.